Trials / Available
AvailableNCT04809233
Expanded Access to Tipifarnib
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Kura Oncology, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Requests for single patient expanded access to tipifarnib may be considered for adult patients with HRAS mutations or peripheral T Cell Lymphoma (PTCL). To request access, use Responsible Party contact information provided in this record. Expanded access for tipifarnib is only available in the United States.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tipifarnib |
Timeline
- First posted
- 2021-03-22
- Last updated
- 2025-06-04
Source: ClinicalTrials.gov record NCT04809233. Inclusion in this directory is not an endorsement.